Annora

SAFETY DATA SHEET

Section 1: Identification	
Material **Recommended use**	Divalproex Sodium Extended-Release Tablets USP 250 mg Pharmaceutical product
Manufacturer	Annora Pharma Private Limited, Survey No. 261, Annaram Village, Gummadidala Mandal, Sangareddy, Telangana 502313, India (IND)
Distributor	**Camber Pharmaceuticals, Inc.**, Piscataway, NJ 08854

Section 2: Hazard(s) Identification	
Fire and Explosion	Expected to be non-combustible
Health	• Divalproex sodium extended-release tablets should not be administered to patients with hepatic disease or significant hepatic dysfunction. • Divalproex sodium extended-release tablets are contraindicated in patients known to have mitochondrial disorders caused by mutations in mitochondrial DNA polymerase γ (POLG; e.g., Alpers-Huttenlocher Syndrome) and children under two years of age who are suspected of having a POLG-related disorder. • Divalproex sodium extended-release tablets are contraindicated in patients with known hypersensitivity to the drug. • Divalproex sodium extended-release tablets are contraindicated in patients with known urea cycle disorders. • For use in prophylaxis of migraine headaches: Divalproex sodium extended-release tablet is contraindicated in women who are pregnant and in women of childbearing potential who are not using effective contraception.
Environment	No information is available about the potential of this product to produce adverse environmental effects.

Section 3: Composition/Information on Ingredients	
Ingredients	**CAS**
Divalproex Sodium	76584-70-8
Hypromellose 2208	9004-65-3

Hydroxy Propyl Methyl Cellulose	9004-65-3
Microcrystalline Cellulose	9004-34-6
Opacode Black S-1-17823 IH	NA
Opadry AMB White	889676-18-0
Silicon Dioxide	7631-86-9

Section 4: First-Aid Measures

Ingestion:	If conscious, give water to drink and induce vomiting. Do not attempt to give any solid or liquid by mouth if the exposed subject is unconscious or semi-conscious. Wash out the mouth with water. Obtain medical attention.
Inhalation	Move individual to fresh air. Obtain medical attention if breathing difficulty occurs. If not breathing, provide artificial respiration assistance.
Skin Contact	Remove contaminated clothing and flush exposed area with large amounts of water. Wash all exposed areas of skin with plenty of soap and water. Obtain medical attention if skin reaction occurs.
Eye Contact	Flush eyes with plenty of water. Get medical attention.
Medical Treatment	Treat according to locally accepted protocols. For additional guidance, refer to the current prescribing information or to the local poison control information center. Protect the patient's airway and support ventilation and perfusion. Meticulously monitor and maintain, within acceptable limits, the patient's vital signs, blood gases, serum electrolytes, etc.
Over dosage	Overdosage with valproate may result in somnolence, heart block, deep coma, and hypernatremia. Fatalities have been reported; however patients have recovered from valproate levels as high as 2,120 mcg/mL. In overdose situations, the fraction of drug not bound to protein is high and hemodialysis or tandem hemodialysis plus hemoperfusion may result insignificant removal of drug. The benefit of gastric lavage or emesis will vary with the time since ingestion. General supportive measures should be applied with particular attention to the maintenance of adequate urinary output. Naloxone has been reported to reverse the CNS depressant effects of valproate overdosage. Because naloxone could theoretically also reverse the antiepileptic effects of valproate, it should be used with caution in patients with epilepsy.

Section 5: Fire-Fighting Measures

Fire and Explosion Hazards	Assume that this product is capable of sustaining combustion

Extinguishing Media	Water spray, carbon dioxide, dry chemical powder or appropriate foam.
Special Firefighting Procedures	For single units (packages): No special requirements needed. For larger amounts (multiple packages/pallets) of product: Since toxic, corrosive or flammable vapors might be evolved from fires involving this product and associated packaging, self-contained breathing apparatus and full protective equipment are recommended for firefighters.
Hazardous Combustion Products	Hazardous combustion or decomposition products are expected when the product is exposed to fire.

Section 6: Accidental Release Measures

Clean-up Methods	Collect and place it in a suitable, properly labeled container for recovery or disposal.
Personal Precautions:	Wear protective clothing and equipment consistent with the degree of hazard.
Environmental Precautions:	For large spills, take precautions to prevent entry into waterways, sewers, or surface drainage systems.

Section 7: Handling and Storage

Handling:	No special control measures required for the normal handling of this product. Normal room ventilation is expected to be adequate for routine handling of this product.
Storage:	Store at 25°C (77°F); excursions permitted to 15° to 30°C (59° to 86°F). [See USP Controlled Room Temperature].

Section 8: Exposure Controls/Personal Protection

Wear appropriate clothing to avoid skin contact. Wash hands and arms thoroughly after handling.

Section 9: Physical and Chemical Properties

Physical Form	White, oval shaped, film coated tablets
Description	Divalproex sodium extended-release tablets USP 250 mg are available as white to off white, oval shaped film-coated tablets imprinting with ‘V 23’ on one side and plain on other side. Bottles of 100 NDC 31722-021-01 Bottles of 500 NDC 31722-021-05 Divalproex sodium extended-release tablets USP 500 mg are available as white to off white, oval shaped film-coated tablets imprinting with ‘V 24’ on one side and plain on other side. Bottles of 100 NDC 31722-022-01 Bottles of 500 NDC 31722-022-05

Section 10: Stability and Reactivity

Stability and reactivity	Stable under recommended storage conditions.

Section 11: Toxicological Information

Carcinogenesis, Mutagenesis, Impairment of Fertility	Valproate was administered orally to rats and mice at doses of 80 and 170 mg/kg/day (less than the maximum recommended human dose on a mg/m2 basis) for two years. The primary findings were an increase in the incidence of subcutaneous fibrosarcomas in high-dose male rats receiving valproate and a dose-related trend for benign pulmonary adenomas in male mice receiving valproate. Valproate was not mutagenic in an in vitro bacterial assay (Ames test), did not produce dominant lethal effects in mice, and did not increase chromosome aberration frequency in an in vivo cytogenetic study in rats. Increased frequencies of sister chromatid exchange (SCE) have been reported in a study of epileptic children taking valproate, this association was not observed in another study conducted in adults. In chronic toxicity studies in juvenile and adult rats and dogs, administration of valproate resulted in testicular atrophy and reduced spermatogenesis at oral doses of 400 mg/kg/day or greater in rats (approximately equal to or greater than the maximum recommended human dose (MRHD) on a mg/m2 basis) and 150 mg/kg/day or greater in dogs (approximately equal to or greater than the MRHD on a mg/m2 basis). Fertility studies in rats have shown no effect on fertility at oral doses of valproate up to 350 mg/kg/day (approximately equal to the MRHD on a mg/m2 basis) for 60 days.

Section 12: Ecological Information

No relevant studies identified

Section 13: Disposal Considerations

Incinerate in an approved facility. Follow all federal state and local environmental regulations.

Section 14: Transport Information

IATA/ICAO - Not Regulated

IATA Proper shipping Name :	N/A
IATA UN/ID No :	N/A
IATA Hazard Class :	N/A
IATA Packaging Group :	N/A
IATA Label :	N/A

IMDG - Not Regulated

IMDG Proper shipping Name :	N/A
IMDG UN/ID No :	N/A
IMDG Hazard Class :	N/A
IMDG Flash Point :	N/A
IMDG Label :	N/A

DOT - Not Regulated

DOT Proper shipping Name :	N/A
DOT UN/ID No :	N/A
DOT Hazard Class :	N/A
DOT Flash Point :	N/A
DOT Packing Group :	N/A
DOT Label :	N/A

Section 15: Regulatory Information

This Section Contains Information relevant to compliance with other Federal and/or state laws

Section 16: Other Information

Issue Date : 14-12-2023

Version : 00

Further information

Revision date: New issue

Revision note: New issue

The information and recommendations in this safety data sheet are, to the best of our knowledge, accurate as of the date of issue. Nothing herein shall be deemed to create any warranty, express or implied. It is the responsibility of the user to determine the applicability of this information and the suitability of the material or product for any particular purpose.

Annora Pharma Private Limited shall not be held liable for any damage resulting from handling or from contact with the above product. Annora Pharma Private Limited reserves the right to revise this SDS.